Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (157)	9/7/2005 1:08:15 PM
From: tuck	Respond to of 368

SGMO signs Novo to technology evaluation deal for ZFP-enabled protein production: >>BAGSVAERD, Denmark and RICHMOND, Calif., Sept. 7 /PRNewswire-FirstCall/ -- Novo Nordisk A/S (NYSE: NVO - News) and Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) today announced an agreement that provides Novo Nordisk with access to Sangamo's proprietary zinc finger DNA-binding protein (ZFP) technology. Sangamo will provide its ZFP technology for Novo Nordisk to evaluate for use in the field of enhanced protein production. "Novo Nordisk recognizes the need for innovative technologies that aid in the rapid development of novel therapies to combat disease," said Esper Boel, Vice-President and Head of Biotechnology of Novo Nordisk. "We look forward to evaluating Sangamo's proprietary technology for enhanced protein production." "We are very pleased to be able to provide Novo Nordisk, the world leader in diabetes care, with our ZFP technology," said Edward Lanphier, Sangamo's president and chief executive officer. "We have engineered ZFP transcription factors that can significantly increase production from genes expressing protein pharmaceuticals and we can engineer zinc finger nucleases (ZFNs(TM)) to facilitate the efficient generation of production cell lines with altered traits. With the increased approval and demand for protein pharmaceuticals, we believe that our technology has an important place in modern drug development." ZFPs are the dominant class of naturally occurring transcription factors in organisms from yeast to humans. Transcription factors, which are found in the nucleus of every cell, bind to DNA to regulate gene expression. Though there are many kinds of transcription factors, only zinc finger DNA-binding proteins are amenable to engineering and precise targeting to a particular gene or genes of interest.<< Cheers, Tuck

To: nigel bates who wrote (157)	11/14/2005 2:35:47 AM
From: tuck	Read Replies (1) \| Respond to of 368

[Sangamo starts preclinical work in neuropathic pain program with TrkA as target] >>RICHMOND, Calif., Nov. 7 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) today announced that data from its program to develop a ZFP Therapeutic(TM) for neuropathic pain were presented at the 8th International Conference on the Mechanisms and Treatment of Neuropathic Pain on November 5, 2005, in San Francisco. The studies report the development of Sangamo's program to use zinc finger DNA-binding protein transcription factors (ZFP TF(TM)) as potential therapeutic agents for the treatment of neuropathic pain. "Our data show that we have designed ZFP TFs that, in human cells and primary nerve cells, can significantly repress the expression of a well-validated gene target for neuropathic pain, TrkA," said Dr. Philip Gregory, Sangamo's vice president of research. "These data are very encouraging and we are in the process of testing this novel approach in animal models including a model of bone cancer pain." "Neuropathic pain represents a significant unmet medical need," said Edward Lanphier, Sangamo's president and CEO. "It is estimated that as many as 80 million people in the US live with chronic pain derived from a variety of sources including back pain and cancer. Annual sales for over-the-counter analgesics alone add up to $3 billion and prescribed drugs account for another $100 billion a year. Only 15-30% of neuropathic pain is treatable using opioids, the most potent existing pain relievers, which have many undesirable side effects. The promise of the "better opioid" that is non-addictive and side effect free has not materialized. We believe that our ability to specifically repress the TrkA gene using ZFP TFs may enable the development of a more effective therapeutic to address neuropathic pain." Neuropathic pain is the result of an injury or malfunction in the peripheral or central nervous system. Such pain can also result from infiltration or compression of nerves by tumors or inflammation of the nerve as a consequence of infection. Neuropathic pain is frequently chronic, and often fails to respond to standard analgesic treatment. Opioids may give a degree of relief, but in many cases only at doses impractical for what may be a lifelong regimen.<< snip Cheers, Tuck